← 홈

Antibody · 폐암 (NSCLC)

212개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-8 · 마지막 7월 21일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 212개
AntibodystaleInstitut BergoniéPhase 2

durvalumab (Imfinzi, Association of lurbinectedin and durvalumab)

Small Cell Lung Cancer; Platinum-Sensitive Lung Small Cell Carcinoma · Small Cell Lung Cancer

#SmallCellLungCancer#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleNavire Pharma Inc., a BridgeBio…Phase 1

nivolumab (Opdivo, BBP-398 with nivolumab)

Non Small Cell Lung Cancer; Solid Tumor · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 DISCONTINUED
AntibodystaleBristol-Myers SquibbPhase 3

BMS-986012+Nivolumab (BMS-986489, BMS-986489 (BMS-986012+Nivolumab))

Extensive-Stage Small Cell Lung Cancer · Extensive-Stage Small Cell Lung Cancer

#Extensive-StageSmallCellLungCanc#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 2

Belinostat, carboplatin, paclitaxel and bevacizumab (Belinostat, carboplatin, paclitaxel and bevacizumab)

Non-Small-Cell Lung Carcinoma · Non-Small-Cell Lung Carcinoma

#Non-Small-CellLungCarcinoma#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleXinqiao Hospital of ChongqingPhase 2

Benmelstobart combined with Bevacizumab and chemotherapy (Benmelstobart combined with Bevacizumab and chemotherapy)

NSCLC Stage IV Without EGFR/ALK Mutation · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
임상시험 1상태 RECRUITING
AntibodystaleRochePhase 3

Bevacizumab + Pemetrexed (Bevacizumab + Pemetrexed)

Non-squamous Non-small Cell Lung Cancer · Non-squamous Non-small Cell Lung Cancer

#Non-squamousNon-smallCellLungCan#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 3

Bevacizumab + Pemetrexed + Carboplatin (Bevacizumab + Pemetrexed + Carboplatin)

Non-squamous Non-small Cell Lung Cancer · Non-squamous Non-small Cell Lung Cancer

#Non-squamousNon-smallCellLungCan#Antibody#Phase3#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab Biosimilar HLX04 (Bevacizumab Biosimilar HLX04)

Non-Squamous Non-Small Cell Lung Cancer · Non-Squamous Non-Small Cell Lung Cancer

#Non-SquamousNon-SmallCellLungCan#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab plus erlotinib (Bevacizumab plus erlotinib)

Carcinoma, Non-Small-Cell Lung; Brain Neoplasms · Carcinoma, Non-Small-Cell Lung

#CarcinomaNon-Small-CellLung#Antibody#Phase2#항체#면역항체+5
임상시험 1상태 ACTIVE
AntibodystaleRochePhase 2

Bevacizumab, Oxaliplatin, Pemetrexed (Bevacizumab, Oxaliplatin, Pemetrexed)

Non-Small Cell Lung Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleNational Cancer Center, KoreaPhase 2

nivolumab (Opdivo, CA and Nivolumab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 ACTIVE
AntibodystaleGerman Cancer Research CenterPhase 2

CC-1 and Toczilizumab (CC-1 and Toczilizumab)

Lung Cancer Squamous Cell · Lung Cancer Squamous Cell

#LungCancerSquamousCell#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 DISCONTINUED
AntibodystaleFamewave Ltd.Phase 2

nivolumab (Opdivo, CM-24 and Nivolumab - Dose Escalation)

Solid Tumor; Non Small Cell Lung Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleFamewave Ltd.Phase 2

nivolumab (Opdivo, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion)

Solid Tumor; Non Small Cell Lung Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleFamewave Ltd.Phase 2

nivolumab (Opdivo, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion)

Solid Tumor; Non Small Cell Lung Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleCorvus Pharmaceuticals, Inc.Phase 1

pembrolizumab (Keytruda, CPI-006 + pembrolizumab)

Non-Small Cell Lung Cancer; Renal Cell Cancer · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase1#항체#면역항체+3
임상시험 1상태 ACTIVE
AntibodystaleIntergroupe Francophone de Canc…Phase 2

durvalumab (Imfinzi, Carboplatin + Paclitaxel + Durvalumab)

Small Cell Lung Cancer Extensive Stage · Small Cell Lung Cancer Extensive Stage

#SmallCellLungCancerExtensiveStag#Antibody#Phase2#항체#면역항체+2
임상시험 1상태 RECRUITING
AntibodystaleCentre Francois BaclessePhase 2

atezolizumab (Tecentriq, Carboplatin + Pemetrexed + Atezolizumab)

NSCLC Stage IIIB; NSCLC Stage IV · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
효능 ORR 64.6%임상시험 1상태 ACTIVE
AntibodystaleCentre Francois BaclessePhase 2

atezolizumab (Tecentriq, Carboplatin + Pemetrexed + Atezolizumab + Bevacizumab)

NSCLC Stage IIIB; NSCLC Stage IV · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+4
효능 ORR 42.9%임상시험 1상태 ACTIVE
AntibodystaleVerastem, Inc.Phase 2

pembrolizumab (Keytruda, Carboplatin + Pemetrexed + Pembrolizumab)

Pancreatic Ductal Adenocarcinoma; Non Small Cell Lung Cancer · Pancreatic Ductal Adenocarcinoma

#PancreaticDuctalAdenocarcinoma#Antibody#Phase2#항체#면역항체+3
임상시험 1상태 RECRUITING

4 / 11 페이지

← 이전다음 →